Esophageal Cancer Surveillance and Follow-up

Scope and principles

The supplied evidence does not establish a single, universally applicable surveillance interval for all patients with esophageal cancer. Surveillance should therefore be based on the treatment pathway, histology, stage, recurrence risk, symptoms, functional status, and whether the patient has undergone endoscopic eradication therapy (EET), endoscopic resection, esophagectomy, definitive chemoradiotherapy, or treatment for advanced disease. ^{[1]A1c[6]A1a[9]B2b[20]C4}

Surveillance is intended to detect treatable local or metachronous neoplasia, locoregional recurrence, distant metastases, treatment-related complications, nutritional decline, and psychosocial or functional problems. The available references support risk-adapted clinical follow-up but do not provide sufficient evidence to mandate one fixed schedule for every clinical scenario. ^{[1]A1c[4]A1b[7]B2a[13]A1b[14]B2a[20]C4}

After endoscopic eradication therapy or endoscopic resection

Patients treated with EET for Barrett’s esophagus (BE) and related neoplasia require structured follow-up endoscopy because EET has potential benefits but also procedural harms, recurrence concerns, and substantial resource use. The AGA guideline emphasizes evidence-based selection of EET and continuing endoscopic surveillance after eradication, but the supplied abstract does not specify interval schedules. ^[1]A1c

After endoscopic resection of esophageal squamous cell carcinoma (ESCC), surveillance endoscopy is recommended because subsequent ESCC can occur. A study defining advanced post-endoscopy lesions used a window of within 24 months after the preceding endoscopy; this should be regarded as evidence that clinically important lesions may arise during the first 2 years, not as a universally validated interval. ^[17]B3b

Patients with pMM/SM1 disease after endoscopic resection require particularly careful, risk-adapted follow-up because long-term outcomes include both metastatic recurrence and second primary esophageal cancer. In a prospective multicenter cohort, 5-year overall survival was 92.3% for ESCC and 94.2% for esophageal adenocarcinoma, but surveillance remains necessary because survival does not eliminate recurrence or second-primary risk. ^[77]

Endoscopic follow-up should assess the resection scar, residual or recurrent neoplasia, metachronous lesions, and treatment-related stenosis. The need for close follow-up is also supported by data showing that endoscopic submucosal dissection and radiofrequency ablation are used for superficial squamous neoplasia, although the available comparative evidence is retrospective and does not define an interval schedule. ^{[16]B3b[18]B3b}

After esophagectomy or definitive chemoradiotherapy

Post-treatment visits should combine symptom review, physical examination, nutritional assessment, treatment-toxicity assessment, and investigation of clinically suspected recurrence. Evidence from salvage radiotherapy cohorts shows that locoregional recurrence after surgery can occur after a variable disease-free interval, with a reported median of 13.5 months; this supports heightened clinical vigilance during the first several years, without proving a specific imaging interval. ^[20]C4

Recurrence risk should be individualized according to pathological status. In resected ESCC after neoadjuvant treatment, pathologic complete response, residual primary tumor, and residual nodal disease were associated with differing prognostic groups, indicating that pathological findings should influence surveillance intensity. ^[71]

Routine surveillance should not automatically include brain imaging in asymptomatic patients. Brain metastases from esophageal carcinoma remain relatively uncommon, although their incidence, presentation, and prognosis have been systematically evaluated; brain MRI or other neuroimaging should be prompted by neurologic symptoms or clinically meaningful suspicion. ^[14]B2a Primary small-cell carcinoma of the esophagus may require a more individualized strategy because predictive models for brain metastasis and brain-metastasis-free survival have been developed in this rare subtype, but these models do not establish a standard surveillance schedule. ^[70]

Follow-up for treatment complications and survivorship

Every follow-up assessment should screen for dysphagia, reflux, aspiration, early satiety, weight loss, diarrhea, postprandial weakness, palpitations, and vasomotor symptoms. Dumping syndrome is sufficiently frequent after esophageal cancer surgery to justify active symptom screening; a systematic review and meta-analysis found substantial prevalence with heterogeneity between studies, and a later cohort evaluated symptoms prospectively up to 24 months after surgery. ^{[2]A1a[11]B2b}

Nutritional and functional surveillance should include weight trajectory, dietary intake, hydration, micronutrient needs, swallowing function, and physical performance. Sarcopenia is associated with worse perioperative outcomes in patients undergoing esophagectomy, supporting continued assessment of muscle mass and functional decline in survivorship care. ^[7]B2a A 12-week walking and dietary-education intervention improved quality-of-life-related outcomes and symptoms during follow-up assessments extending to 12 months, supporting referral to rehabilitation and nutrition services when indicated. ^[4]A1b

Thromboembolic risk should be reviewed after surgery and during recurrence surveillance. A randomized study evaluated 1 month of low-molecular-weight heparin versus standard in-hospital prophylaxis after esophagectomy, but the supplied evidence does not establish a surveillance visit schedule or universal duration of prophylaxis. ^[5]A1b

Advanced or recurrent disease

For patients receiving systemic therapy for advanced disease, follow-up should be coordinated with treatment cycles and response assessment, using symptoms, examination, laboratory monitoring, and imaging according to treatment intent and clinical status. Long-term KEYNOTE-590 follow-up supports durable outcome assessment for pembrolizumab plus chemotherapy in advanced esophageal cancer, but it does not define a post-treatment surveillance schedule. ^[3]A1b

Patients with oligometastatic disease require multidisciplinary reassessment because reported management strategies include systemic therapy, local treatment, combined local and systemic therapy, or best supportive care. Surveillance intensity should reflect the selected treatment and the sites of disease. ^[13]A1b Recurrence-free or event-free survival may help evaluate treatment effectiveness, but studies validating these endpoints as surrogates for overall survival do not prescribe clinical follow-up intervals. ^[6]A1a[9]B2b

Practical schedule framework

Use an early postoperative or post-treatment visit to establish recovery, nutrition, swallowing, medication needs, and baseline symptoms; continue visits at clinically appropriate intervals during the period of greatest recurrence risk; and extend intervals only when disease status and functional recovery are stable. Endoscopy should follow the disease-specific EET or endoscopic-resection pathway, while cross-sectional imaging and additional tests should be symptom- and risk-directed rather than indiscriminate. This framework reflects the evidence available here and should be adapted to local multidisciplinary protocols. ^{[1]A1c[17]B3b[20]C4[77]}

Urgent reassessment is required for progressive dysphagia, recurrent vomiting, bleeding, rapid weight loss, new focal pain, respiratory deterioration, persistent neurologic symptoms, or other findings suggesting recurrence or a serious treatment complication. ^{[2]A1a[4]A1b[11]B2b[14]B2a[20]C4}

Purpose and clinical framework

Post-treatment surveillance should be directed toward detecting locoregional recurrence, nodal disease, distant metastases, and second or metachronous upper-gastrointestinal neoplasia, because recurrence may be amenable to salvage treatment or selected metastasis-directed therapy. ^{[13]A1b[20]C4} Recurrence after curative-intent resection is clinically important but is not consistently represented in structured electronic-health-record fields, creating a need for systematic clinical and data-based detection. ^[79]

Assessment should be triggered by new or progressive symptoms, abnormal examination findings, or surveillance abnormalities. Symptoms may be nonspecific; for example, small-bowel metastases from esophageal squamous cell carcinoma have been reported with abdominal symptoms and intestinal obstruction, emphasizing that recurrence should remain in the differential diagnosis when patients develop unexplained gastrointestinal complaints. ^[78] Locoregional relapse after surgery has been treated with salvage radiotherapy or chemoradiotherapy, while locally recurrent lesions after definitive chemoradiotherapy may be considered for salvage photodynamic therapy in selected patients. ^[20]C4[31]C4

Endoscopic detection

Upper endoscopy remains central when recurrence is suspected within the esophageal lumen or at an anastomotic site, allowing direct inspection and tissue diagnosis. Its diagnostic performance may be enhanced by artificial-intelligence assistance: a 2026 systematic review and meta-analysis of randomized trials evaluated real-time AI-assisted esophagogastroduodenoscopy against conventional endoscopy for upper-gastrointestinal neoplasm detection, using pooled risk ratios for detection and incidence-rate ratios for lesions per endoscopy. ^[73] The evidence supports AI as an adjunct to lesion recognition, but the cited abstract does not establish a recurrence-specific surveillance interval, a replacement for expert endoscopy, or a universal AI system. ^[73]

Endoscopic surveillance is also relevant after endoscopic treatment of superficial neoplasia, because recurrence-free outcomes differ according to treatment modality. In a retrospective comparison of widespread superficial esophageal squamous neoplasia, endoscopic submucosal dissection and radiofrequency ablation were evaluated using recurrence-free survival as the primary outcome; the study reported high en-bloc and R0 resection rates for dissection, but comparative long-term surveillance remains necessary. ^[18]B3b A separate meta-analysis compared endoscopic submucosal tunnel dissection with conventional submucosal dissection and included recurrence among its secondary outcomes, although its principal focus was resection efficacy and safety rather than post-treatment recurrence detection. ^[27]B2a

Cross-sectional and functional imaging

Contrast-enhanced CT is used for diagnosis and initial staging of esophageal squamous cell carcinoma, and CT-based assessment remains relevant when recurrence is suspected. ^[24]A1b CT radiomics has additionally been investigated for predicting early recurrence after trimodal therapy; in that study, early recurrence was defined as recurrence within 1 year after surgery, including local, distant, lymph-node-positive, and disseminated patterns. ^[24]A1b Radiomics should therefore be regarded as a risk-stratification or prediction tool rather than a standalone diagnostic test for established recurrence, because the cited evidence concerns model development and prediction. ^[24]A1b

When metastatic disease is identified, 18F-FDG-PET/CT can define the distribution and burden of disease. In a multicenter cohort, de-novo oligometastatic disease was defined as ≤5 distant metastases on 18F-FDG-PET/CT; patients were categorized according to systemic therapy, local treatment, combined local and systemic treatment, or best supportive care. ^[13]A1b This threshold is a study definition, not a universal rule for all recurrence decisions. ^[13]A1b

Diffusion-weighted MRI has been studied primarily for response assessment during concurrent chemoradiotherapy rather than for routine recurrence detection. Serial apparent-diffusion-coefficient measurements were obtained during treatment and tumor response was assessed with RECIST in a prospective cohort of esophageal squamous cell carcinoma patients. ^[23]C4 Accordingly, DWI may provide treatment-response information, but the cited evidence does not validate it as a general-purpose surveillance test for post-treatment recurrence. ^[23]C4

Electronic detection and emerging adjuncts

Automated review of electronic records may improve case ascertainment. A single-center retrospective study developed a rule-based natural-language-processing algorithm using pathology and radiology reports after R0 gastrectomy or esophagectomy; definitive pathology statements were prioritized, while imaging-based recurrence required confirmation criteria. ^[79] This approach may reduce the workload of manual chart review, but it is an informatics detection system rather than a patient-facing diagnostic test, and its single-center retrospective design limits generalizability. ^[79]

Minimally invasive sampling methods are emerging for detection of esophageal squamous neoplasia. The prospective EDEN proof-of-concept study evaluated capsule-sponge sampling with p53 immunohistochemistry against high-definition endoscopy in healthy controls, high-risk individuals with previous head-and-neck cancer, and patients with early-stage esophageal squamous neoplasia. ^[22]C4 Because this study addressed early detection and not established post-treatment recurrence, capsule-sponge testing should not currently be substituted for diagnostic endoscopy when recurrence is suspected. ^[22]C4

Interpreting recurrence-related evidence

Recurrence-free or disease-free survival is an important outcome for surveillance and treatment studies, but a 2025 meta-analysis evaluated whether these endpoints serve as surrogates for overall survival in resectable esophageal-cancer trials rather than defining a surveillance test. ^[25]B2a Similarly, evidence concerning stage I brachytherapy, p16 methylation, screening acceptance, and population screening addresses treatment, molecular biology, or primary detection rather than recurrence surveillance. ^{[26]B2a[28]B2a[10]B2a[74][75]} Esophageal gastrointestinal stromal tumors are rare and have distinct biology; evidence supporting endoscopic resection in selected low-risk tumors should not be extrapolated to routine surveillance of esophageal carcinoma. ^[30]B3b Treatment-response studies of immune-checkpoint inhibitors and immune-related adverse events concern patients with unresectable or recurrent disease and may inform management after recurrence is established, but they do not provide a recurrence-detection strategy. ^{[67]B3b[29]C4}

In practice, suspected recurrence should therefore be confirmed using the modality appropriate to its anatomic presentation—endoscopy with biopsy for luminal or anastomotic abnormalities, contrast-enhanced cross-sectional imaging with or without PET/CT for nodal or distant disease, and targeted investigations for unusual symptomatic sites. ^{[13]A1b[20]C4[23]C4[24]A1b[78]} AI endoscopy, radiomics, DWI, and automated EHR review are promising adjuncts, but the supplied evidence does not support replacing clinician-directed evaluation or histologic confirmation where feasible. ^{[73][23]C4[24]A1b[79]}

Survivorship assessment and follow-up priorities

Survivorship follow-up should extend beyond recurrence surveillance to include nutrition, swallowing, gastrointestinal symptoms, physical function, psychological health, social recovery, and caregiver needs. Patients and families report that persistent symptoms and reduced quality of life are common after oesophago-gastric surgery, while conventional follow-up has often concentrated primarily on recurrence and survival. ^[54]D5 In a patient-perspective survey, respondents identified postoperative symptoms and functional consequences as important determinants of quality of life and expressed preferences regarding the structure and content of follow-up. ^[54]D5

A multidisciplinary survivorship model can incorporate validated patient-reported outcome measures, functional review, anthropometry, and biochemical assessment for micronutrient deficiencies at 6 and 12 months after oesophagectomy. ^[50]D5 An early nutrition and survivorship clinic reported the feasibility of this approach in 75 patients, most of whom had adenocarcinoma and multimodal treatment; the clinic specifically focused on nutritional well-being and recovery after surgery. ^[50]D5 Nutritional-support strategies may be surgical, endoscopic, or radiological, but their comparative effects on patient-reported outcomes remain uncertain because the available evidence is heterogeneous. ^[40]B2a

Nutritional and gastrointestinal sequelae

Dumping symptoms are a clinically important late consequence after oesophageal cancer surgery. In a prospective Swedish cohort assessed 1 year after surgery, both early- and late-onset dumping symptoms were evaluated according to symptom intensity and examined in relation to health-related quality of life, with reassessment at 1.5 years. ^[38]B2b Moderate or severe dumping symptoms were specifically associated with the study’s HRQL outcomes, supporting routine symptom-directed questioning rather than relying only on weight or nutritional laboratory results. ^[38]B2b

Recurrent benign anastomotic or conduit strictures may produce persistent dysphagia and impaired quality of life. Mechanical dilation remains the standard treatment, but refractory strictures may persist despite repeated procedures. ^[44]B2b A prospective, nonrandomized eight-centre trial evaluated a biodegradable stent in patients with refractory benign strictures who had undergone at least 5 dilations or at least 1 radial incision and cutting procedure, had a dysphagia score of 2 or worse, and had an endoscope that could not pass the stricture. ^[44]B2b Such patients require specialist reassessment, including endoscopic evaluation and consideration of advanced therapy when repeated dilation is unsuccessful. ^[44]B2b

Long-term health-related quality of life

Long-term HRQL remains affected after apparently curative oesophagectomy, although outcomes may vary by surgical approach and individual recovery. Disease-free patients assessed more than 2 years after transthoracic or transhiatal oesophagectomy were evaluated with EORTC QLQ-C30 and QLQ-OG25 instruments; the study specifically examined long-term HRQL in distal oesophageal and gastro-oesophageal junction cancer. ^[48]D5 A related comparison of McKeown and Ivor Lewis oesophagectomy evaluated disease-free patients more than 1 year after surgery using the same core and oesophageal modules. ^[49]D5

Postoperative complications may have durable consequences. In the European LASER dataset, disease-free patients assessed more than 1 year after oesophagectomy were compared according to whether complications occurred and according to complication severity, with long-term HRQL as the outcome. ^[53]D5 These findings support documenting major postoperative complications in survivorship records and actively assessing patients with persistent functional or psychological symptoms rather than assuming that resolution of acute morbidity represents full recovery. ^[53]D5

Frailty, rehabilitation, and physical recovery

Frailty and functional reserve should be assessed before and after treatment, particularly in older adults. A feasibility study used the 6-minute walk test, gait speed, hand-grip strength, comorbidity and frailty indices, quality-of-life questionnaires, and CT-based psoas muscle assessment before thoracic surgery for lung or oesophageal cancer. ^[45]C4 In a prospective longitudinal study of 131 older patients undergoing oesophageal cancer surgery, frailty and HRQL were measured preoperatively and at 1 week, 1 month, and 3 months postoperatively to examine their relationship over time. ^[43]B3b

Postoperative rehabilitation may include pulmonary exercises, inspiratory muscle training, coughing techniques, mobility, stretching, and broader multimodal components. A retrospective study of 59 inpatients compared multimodal inpatient rehabilitation with conventional pulmonary rehabilitation after oesophageal cancer surgery and evaluated physical recovery. ^[41]B3b Before or during neoadjuvant therapy, a randomized feasibility trial compared supervised and home-based exercise while providing identical nutritional and psychosocial support; recruitment, retention, and dropout were primary feasibility outcomes. ^[39]C4 A separate randomized trial evaluated a 12-week walking and dietary-education program, with quality of life, anxiety, depression, rest/activity circadian rhythm, and sleep assessed through 12 months. ^[4]A1b

Psychological, caregiver, and social survivorship needs

Psychological distress should be assessed longitudinally. A study of the Managing Cancer and Living Meaningfully intervention reported reductions in psychological distress, anxiety, and depression and improvement in quality of life, with benefit persisting at 1 month after the intervention. ^[51]D5 Informal caregivers of people with upper gastrointestinal cancers experience adjustment challenges and have supportive-care needs that are insufficiently characterized in the qualitative evidence base. ^[37]B2a Follow-up should therefore offer caregiver-inclusive education, signposting, and psychosocial assessment. ^[37]B2a

Employment and social functioning may also be affected during the treatment pathway. A multicentre Japanese cross-sectional study examined job resignation between diagnosis and surgery among employed patients scheduled for curative-intent surgery for gastric or oesophageal cancer and assessed associated HRQL correlates. ^[76] Work status, financial concerns, and return-to-work goals should consequently be included in individualized survivorship assessment. ^[76]

Treatment-related late toxicity beyond surgery

Esophageal brachytherapy has been used as exclusive treatment, as a boost after external-beam radiotherapy, for reirradiation, and for palliation. A retrospective single-centre series of 90 patients treated between 1992 and 2018 described high-dose-rate brachytherapy experience across these indications and reported late follow-up toxicity outcomes. ^[42]C4 Patients previously receiving brachytherapy or reirradiation require individualized assessment for delayed dysphagia, stricturing, ulceration, bleeding, and other local complications, with investigation guided by symptoms and treatment history. ^[42]C4

Practical survivorship checklist

At each clinically appropriate review, assess swallowing and reflux-related symptoms, dumping, weight trajectory, oral intake, enteral-support requirements, micronutrient risk, functional capacity, frailty, respiratory recovery, sleep, anxiety or depression, caregiver strain, and work or financial concerns. ^{[38]B2b[40]B2a[41]B3b[43]B3b[50]D5[51]D5[54]D5[76]} Persistent or progressive dysphagia warrants endoscopic evaluation, and refractory strictures should be discussed with an experienced therapeutic endoscopy team. ^[44]B2b Survivorship care should be multidisciplinary and responsive to patient-reported priorities, because long-term HRQL is influenced by symptoms, complications, treatment approach, physical function, and psychosocial recovery. ^{[48]D5[49]D5[53]D5[54]D5}

Purpose of counselling

Follow-up counselling should address not only recurrence surveillance but also recovery, health-related quality of life (HRQoL), symptoms, daily functioning, and work-related concerns. The available evidence includes a randomized trial of rehabilitation after esophageal cancer, a long-term HRQoL study after esophagectomy, and a multicenter study of employment changes before surgery. ^{[4]A1b[48]D5[76]}

Recovery, activity, and diet

Patients may be offered structured support for physical activity and dietary self-management as part of survivorship care. In a two-parallel-arm randomized controlled trial, patients with esophageal cancer were assigned either to standard care or to a 12-week program combining walking exercise with diet education. ^[4]A1b The trial assessed quality of life using the EORTC QLQ-C30 and the esophageal-specific QLQ-OES18, and also evaluated anxiety, depression, rest/activity circadian rhythm, and sleep. ^[4]A1b Outcomes were measured at baseline and at 3, 6, and 12 months, allowing counselling to address both early recovery and persistence of symptoms over the first year. ^[4]A1b

Patients should be told that the available trial was designed to evaluate a combined walking-and-diet intervention rather than walking or diet education in isolation. ^[4]A1b The supplied abstract describes the outcomes and follow-up schedule but does not provide the numerical results; therefore, the magnitude and statistical significance of benefit should not be presented as established from this citation alone. ^[4]A1b A practical discussion can focus on whether the patient can participate, what dietary problems are present, and how activity, sleep, mood, and daily functioning will be reviewed at subsequent visits. ^[4]A1b

Long-term quality of life after esophagectomy

Patients who remain disease-free after treatment should be counselled that HRQoL may remain an important survivorship issue beyond the initial postoperative period. A study specifically evaluated long-term HRQoL in disease-free patients who had undergone transthoracic or transhiatal esophagectomy for distal esophageal or gastro-esophageal junction cancer and whose follow-up exceeded 2 years. ^[48]D5 Participants completed the EORTC QLQ-C30 and QLQ-OG25 questionnaires, and the investigators used uni- and multivariable linear regression to examine HRQoL in the overall cohort and in subgroups defined by minimally invasive esophagectomy and neoadjuvant therapy. ^[48]D5

Counselling should therefore invite patients to report persistent or late problems rather than assuming that completion of treatment means complete recovery. Relevant concerns for structured review include general functioning, symptoms captured by the QLQ-C30, and esophageal or gastroesophageal symptoms captured by the QLQ-OG25. ^[48]D5 The supplied abstract does not include the study’s numerical HRQoL results or identify which surgical approach or treatment subgroup had better outcomes; definitive comparative claims should consequently be avoided. ^[48]D5

Employment and financial concerns

Work status should be discussed proactively, particularly before surgery. A multicenter cross-sectional study in Japan included 167 employed patients with gastric or esophageal cancer scheduled for curative-intent surgery across nine institutions between September 2022 and March 2024. ^[76] Seven patients, equivalent to 4.2%, resigned from work between cancer diagnosis and surgery. ^[76] The study collected socioeconomic information and preoperative HRQoL using the EORTC QLQ-C30 and QLQ-OG25. ^[76]

Patients should be encouraged to raise concerns about leave, job retention, workplace communication, insurance, transportation, and financial support early enough for referral to an oncology social worker or relevant employment service. This is a counselling implication of the study’s focus on resignation, socioeconomic variables, and HRQoL, not evidence that any particular intervention prevents job loss. ^[76] The exploratory modified Poisson regression did not identify statistically significant predictors of resignation in the supplied abstract, so individual risk should not be inferred from a specific demographic or clinical characteristic using this study alone. ^[76]

Shared follow-up planning

A patient-centred follow-up plan should document symptoms, nutritional and activity goals, sleep and mood concerns, HRQoL, and work or financial priorities. The rehabilitation trial supports repeated assessment at baseline and 3, 6, and 12 months, while the long-term esophagectomy study supports continuing HRQoL review after more than 2 years in disease-free survivors. ^[4]A1b[48]D5 Counselling should explain that these studies used validated EORTC instruments, but the evidence supplied here does not establish a universal counselling schedule or prove that a specific exercise, diet, surgical approach, or employment intervention improves outcomes. ^{[4]A1b[48]D5[76]}

Part of the Esophageal Cancer family. Cross-cutting management is split across dedicated child pages:

• Esophageal Cancer , diagnostic page (definition, epidemiology, staging, biomarkers, prognosis)
• Esophageal Cancer Surgical Management , operations by stage, fertility-sparing options, sentinel node mapping, adjuvant triggers (Sedlis / Peters)
• Esophageal Cancer Radiation Management , EBRT + image-guided brachytherapy + concurrent chemoradiation, dose / fractionation, OAR constraints
• Esophageal Cancer Systemic Therapy , concurrent / adjuvant / metastatic chemotherapy, targeted therapy, immune checkpoint inhibitors
• Esophageal Cancer Palliative Care , early integration, symptom management, palliative procedures, end-of-life care
• Esophageal Cancer Recurrent and Metastatic Disease , local-regional salvage, distant metastatic systemic therapy, oligometastatic disease

Pearl: Use these links to hop between management modalities; the parent Esophageal Cancer page carries diagnosis + staging that informs every decision here.